GSK commits US$30b to R&D, factory expansion in US as Trump visits UK.
Drugmaker GSK said on Wednesday it would invest US$30 billion (RM125.7 billion) in US research and development (R&D) and supply chain infrastructure over five years, after US President Donald Trump arrived in Britain for a second state visit to seal investment deals.
The company said its new facilities in the US, which made up half its revenue last year, would “bridge R&D and manufacturing across both the US and UK, strengthening the two countries’ leadership in life sciences”.
GSK’s investment includes US$1.2 billion to build a new factory in Pennsylvania that will produce new medicines for respiratory disease and cancer, with construction to commence in 2026.
It will invest in artificial intelligence, digital technology, new drug substance manufacturing, and improved device assembly at GSK’s five US sites.
London-based GSK is the latest drugmaker to scale up its US footprint as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes.
“This landmark investment will create tens of thousands of American jobs and ensure that critical medicines and technologies are developed and manufactured right here on US soil — where they belong,” US Commerce Secretary Howard Lutnick said in a statement shared by GSK.
Source: theedgemalaysia